
- XV Eurasian Hematology-Oncology Congress - EHOC 2024
- XIV Eurasian Hematology-Oncology Congress - EHOC 2023
- 8th Eurasian Hematology Oncology Summit
- XIth Eurasian Hematology-Oncology Congress - EHOC 2020
- 7th Eurasian Hematology Oncology Summit
- Xth Eurasian Hematology-Oncology Congress
- Events
Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Risk Stratification and Treatment of CLL: If New Drugs Available, 17p / TP53 Should Be Tested at 1st-Line and Relapse/Refractory
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Robin Foa
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Robin Foa
0 views
December 20, 2019
Comments 0
Login to view comments.
Click here to Login
Hematologic Oncology